Elnaggar, Muhammad
Agte, Sarita
Restrepo, Paula
Ram, Meghana
Melnekoff, David
Adamopoulos, Christos
Stevens, Mark M.
Kappes, Katerina
Leshchenko, Violetta
Verina, Daniel
Jagannath, Sundar
Poulikakos, Poulikos I.
Parekh, Samir
Laganà, Alessandro
Funding for this research was provided by:
NIH/NCI (1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), P.I. Poulikakos is supported by the NIH/NCI (R01CA204314, R01CA240362, and R01CA238229), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), P.I. Poulikakos is supported by the NIH/NCI (R01CA204314, R01CA240362, and R01CA238229), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh), 1R01CA244899-01A1 – Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh))
Mount Sinai Health System
Article History
Received: 14 June 2022
Accepted: 5 August 2022
First Online: 17 August 2022
Change Date: 8 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13045-023-01449-x
Declarations
:
: All the samples have been collected from the patient under study ID # 18-00456 approved by the institutional review board (IRB) of Icahn school of Medicine at Mount Sinai.
: The patient was physician-referred as part of the MM banking protocol approved by the Mount Sinai Institutional Review Board. Written informed consent was obtained before samples collection.
: P.I. Poulikakos reports research grants to the Institution by Black Diamond Therapeutics and Verastem Oncology. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen.